Zim Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/56c5z6jm15y3roa4smjcusd2.pdf

Key Takeaways


EU-GMP Remediation: The Central Catalyst

Dr. Anwar Daud: "We have received reactions which do not warrant any further work. They require further clarification and a little more documentation, which are in the process of preparation. And within a few days, we will be responding with our set of documents on the clarifications that are being asked for. So, I believe we are almost at the end of this process."

Revenue Trajectory & Market Access

Zain Daud: "The clients are continuously behind us to supply. All we are waiting for is EU-GMP. ... the demand seems to be there. The orders are there. It is just the regulatory clearance we are waiting for."

Margin Structure & Cost Reset

Zain Daud: "A lot of it has also been capitalized because it has been infrastructure and systems we have put in for the EU-GMP remediation. There are a lot of consultant costs and one-time expenses which we have to do in terms of OPEX, which you are right, will not repeat going forward in H2 also and next year. So, we are looking to be a bit leaner on that part."

Innovation-Led Portfolio: NIP & OTF


Balance Sheet & Investment Footprint

Zain Daud: "We feel that we don't need to do substantial CAPEX to complete all of the orders that will come in till 2030. I think we may need to do some operational CAPEX, which comes with the business as pharma is to upgrade some of the machinery if it comes, but nothing substantial is needed."

Segment & Geographic Mix

Segment / MarketTrendCommentary
Pharmaceutical (core)▲ SteadyContributed ~₹83 crore or 79% of total operating income in Q2; H1 FY27 pharma revenue grew 16% YoY.
Nutraceutical▲ Strong growthGrew 58% YoY in H1 FY27; facility modernized with new automated setup now operational.
NIP & OTF▲ Scaling84% YoY growth in Q2; 14% of total income; EU registration seen as the major acceleration trigger.
Exports▲ Broad-basedContributed ~86% of total operating income in Q2; LATAM, Southeast Asia, Middle East, and Africa all contributed almost equally to export growth.
Australia▲ New entryTGA certification received; first test order in hand; commercial supplies Q3, meaningful revenue from Q4.
Saudi Arabia▬ Pre-revenueNo revenue impact in H1 as Saudi commercials have not yet started for Zim.

Guidance & Commitments

CommitmentSpecificsTimeline
EU-GMP clarification responseSubmit documentation responding to authority clarificationsWithin a few days from the call
EU-GMP certificate receiptCertificate expected 1-1.5 months after CAPA acceptance, subject to EMA meeting cadence1-1.5 months post-acceptance
UK commercial suppliesSupplies to begin once CAPA acceptance confirmed by authoritiesUpon CAPA acceptance
Australia commercial suppliesCommercial supplies to beginQ3 FY27
FY27 revenue without EU₹415-420 croreFY27 full year
FY27 revenue with EU orders in Q4₹450-460 croreFY27 full year
H2 FY27 growth over H110% base growth; 15-20% growth on H1 numberH2 FY27
EBITDA margin normalizationReturn to previous margin levels once revenue crosses ₹430-440 crore; normalized EBITDA margin expected next yearNext year
Long-term EBITDA margin18-20% at ~₹700 crore revenueWhen ₹700 crore revenue achieved
Capacity sufficiencyNo substantial CAPEX needed to fulfill ordersThrough 2030

Key Metrics

MetricQ2 FY27
Total operating income₹105.4 cr, +19% YoY and +12% QoQ
EBITDA₹7.7 cr, broadly flat YoY vs ₹7.8 cr in Q2 FY26; margin 7.3% vs 3.7% in Q1 FY27
EBITDA margin7.3%, improved 365 bps QoQ; lower YoY owing to cost base set-up for new businesses
Net loss₹2.1 cr, narrowed from ₹4 cr in Q1 FY27
Pharmaceutical revenue₹83 cr, 79% of total operating income
NIP and OTF revenue₹14.9 cr, +84% YoY; 14% of total operating income, or 16% including dossier license fees
Export contribution86% of total operating income
R&D allocation₹9.9 cr, 9.4% of total operating income, including ₹4.5 cr for bio-equivalent studies and regulatory filings
Total debt₹146.2 cr, comprising term loan of ₹84.1 cr and working capital loan of ₹62.1 cr
Gross block₹418.8 cr, up from ₹386.2 cr at end of FY26
Marketing authorizations received4, 1 NIP product and 3 OTF products
Filings across Pharmerging and ROW markets48
NIP products at end of procedure stage in EU3
One-time expenses (EU-GMP remediation, consultation fees)₹5.5 cr in H1 FY27, expected to reduce going forward